We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+10.03%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$36.4M
AUM Growth
Cap. Flow
+$37.7M
Cap. Flow %
103.47%
Top 10 Hldgs %
37.91%
Holding
76
New
76
Increased
Reduced
Closed

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 45.69%
2 Energy 26.92%
3 Utilities 4.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PAA icon
26
Plains All American Pipeline
PAA
$17.4B
$571K 1.57%
+24,737
New +$666K
TVTX icon
27
Travere Therapeutics
TVTX
$5.33B
$552K 1.52%
+28,634
New +$572K
SE
28
DELISTED
Spectra Energy Corp Wi
SE
$422K 1.16%
+17,608
New +$468K
CEQP
29
DELISTED
Crestwood Equity Partners LP
CEQP
$407K 1.12%
+19,580
New +$443K
PAA icon
30
CALL
Plains All American Pipeline
PAA
$17.4B
$347K 0.95%
+15,000
New +$404K
ADXS
31
DELISTED
Advaxis Inc
ADXS
$334K 0.92%
+2,216
New +$381K
ATRA icon
32
Atara Biotherapeutics
ATRA
$71.2M
$321K 0.88%
+485
New +$367K
BLCM
33
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$306K 0.84%
+1,509
New +$270K
RXDX
34
DELISTED
Ignyta, Inc.
RXDX
$303K 0.83%
+22,638
New +$273K
PRTK
35
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$300K 0.82%
+15,819
New +$302K
ISEE
36
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$293K 0.8%
+3,735
New +$216K
ARWR icon
37
Arrowhead Research
ARWR
$12.1B
$292K 0.8%
+47,549
New +$270K
TVRD
38
Tvardi Therapeutics
TVRD
$23.5M
$292K 0.8%
+481
New +$264K
GERN icon
39
Geron
GERN
$911M
$288K 0.79%
+59,436
New +$239K
PTLA
40
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$286K 0.79%
+5,561
New +$270K
INSM icon
41
Insmed
INSM
$23.2B
$285K 0.78%
+15,716
New +$277K
SRE icon
42
Sempra
SRE
$60.8B
$284K 0.78%
+6,034
New +$298K
IMMU
43
DELISTED
Immunomedics Inc
IMMU
$284K 0.78%
+92,480
New +$258K
SGMO
44
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$282K 0.77%
+30,847
New +$238K
CLVS
45
DELISTED
Clovis Oncology, Inc.
CLVS
$280K 0.77%
+7,999
New +$516K
ACAD icon
46
Acadia Pharmaceuticals
ACAD
$4.25B
$279K 0.77%
+7,814
New +$275K
SRPT icon
47
Sarepta Therapeutics
SRPT
$1.66B
$278K 0.76%
+7,203
New +$234K
RLYP
48
DELISTED
RELYPSA INC COM
RLYP
$278K 0.76%
+9,802
New +$211K
LJPC
49
DELISTED
La Jolla Pharmaceutical Company
LJPC
$277K 0.76%
+10,250
New +$279K
MGNX icon
50
MacroGenics
MGNX
$235M
$276K 0.76%
+8,911
New +$271K

Similar funds

Virtus ETF Advisers's Q4 2015 Portfolio in Review

Q4 2015 is the first quarter with a 13F filing on record for Virtus ETF Advisers, which disclosed 76 positions worth $36.4M. Its ten largest holdings account for 38% of the portfolio.

Its largest position is Magellan Midstream Partners, L.P.: 42,311 shares worth $2.87M.

By sector, the portfolio is most concentrated in Healthcare at 46% of assets, followed by Energy and Utilities.

  • Virtus ETF Advisers's largest Q4 2015 buy was Magellan Midstream Partners, L.P.: 42,311 shares worth $2.87M.
  • Virtus ETF Advisers's ten largest holdings make up 38% of its $36.4M portfolio in Q4 2015.
  • Virtus ETF Advisers disclosed 76 positions in Q4 2015, its first 13F filing on record.

Based on Virtus ETF Advisers's 13F filing for Q4 2015, filed 16 Feb 2016.